

09/155605



#4

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 9/127</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/00069</b>  <b>(43) International Publication Date:</b> 7 January 1993 (07.01.93)
<b>(21) International Application Number:</b> PCT/NL92/00112 <b>(22) International Filing Date:</b> 26 June 1992 (26.06.92)  <b>(30) Priority data:</b> 91201651.6 26 June 1991 (26.06.91) EP <b>(34) Countries for which the regional or international application was filed:</b> NL et al.  <b>(71) Applicant (for all designated States except US):</b> BROCADES PHARMA B.V. [NL/NL]; Elisabethhof 19, NL-2353 EW Leiderdorp (NL).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> DE VRINGER, Tom [NL/NL]; Juweellaan 173, NL-2719 SB Zoetermeer (NL). MOLLEE, Hinderikus, Marius [NL/NL]; Glen Millerstraat 27, NL-2324 LN Leiden (NL).		<b>(74) Agents:</b> HUYGENS, Arthur, Victor et al.; Gist-Brocades N.V., Patents and Trademarks Department, Wateringseweg 1, P.O. Box 1, NL-2600 MA Delft (NL).  <b>(81) Designated States:</b> CA, JP, US.  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> VESICLES IN NON-POLAR MEDIA  <b>(57) Abstract</b>  Dispersions of vesicles in a non-polar phase are provided, the vesicles, which encapsulate a non-polar phase, comprising a surfactant or a mixture of surfactants, and, if necessary, dependent on the choice of the surfactant(s) and non-polar phase, also a lipophilic stabilizing factor and occasionally a hydrophilic stabilizing factor too. For the preparation of said dispersions of vesicles, several methods, comprising preparing a mixture of all components, optionally at an elevated temperature and/or by the use of organic solvents, are provided. Said dispersions of vesicles may be used in pharmaceutical, cosmetical, food and pesticide preparations and in preparations for treating surfaces in general.		



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

- 1 -

VESICLES IN NON-POLAR MEDIA

The present invention is concerned with novel vesicles,  
5 their preparation and their applications.

## BACKGROUND OF THE INVENTION

Several types of surfactant-based vesicles are known.  
10 Examples are liposomes, NIOSOMES® and "paucilamellar lipid vesicles". In fact, NIOSOMES® and "paucilamellar lipid vesicles" are special types of liposomes.

Liposomes are the most familiar vesicles and were described for the first time by Bangham in 1964 [A.D. Bangham, R.W. Horne,  
15 J. Mol. Biol. 8, 660 (1964)]. Liposomes consist of an aqueous core (AC, Figure 1) encapsulated by one or more spherically closed lamellar sheets. In turn, these lamellar sheets consist of bilayers (BL) of surfactant molecules (SM). Like the core of a liposome the external phase is water or an aqueous solution.

20 The lipophilic tails (LT) of the surfactant molecules in a bilayer are arranged in such a way that they are in close contact with each other and that contact between these lipophilic tails and the aqueous internal and external phases is avoided. On the other hand, the hydrophilic heads (HH) of the  
25 surfactant molecules are fully hydrated. In this way the system reaches the thermodynamically most favourable situation. If a liposome consists of more than one bilayer, the sequential bilayers (SB) are separated by aqueous layers. In case of Multilamellar Lipid Vesicles (MLV's) hydrophilic domains (HD)  
30 alternate lipophilic domains (LD).

Several types of liposomes can be distinguished. The classification is based on the size of the liposomes and the number of bilayers building up the vesicle. A Small Unilamellar Vesicle (SUV) is relatively small (e.g. 50 nm) and consists of  
35 only one bilayer enclosing an aqueous core. Large Unilamellar Vesicles (LUV's) may have sizes up to several micrometers. The

critical size which determines whether a vesicle is called small or large is not well defined in the prior art.

Vesicles consisting of more than one bilayer are called Multilamellar Lipid Vesicles (MLV's). Sometimes the name "paucilamellar lipid vesicles" is used for MLV's which are built up of only a few (2-8) bilayers [see: WO 88/06883]. More details about the classification can be found in: N. Weiner et al., Drug Dev. Ind. Pharm., 15 (10) 1523-1554 (1989).

The surfactants building up the bilayers of a liposome can be ionic (e.g. phospholipids) and/or non-ionic (e.g. polyoxyethylene alkyl ethers). At first, the name NIOSOMES® was reserved for non-ionic surfactant vesicles, not containing any ionic surfactant molecules [R.M. Handjani-Vila et al. Int. J. Cosm. Sci., 1, 303-314 (1979)]. Nowadays, also ionic surfactant molecules may be incorporated in the bilayers of the NIOSOMES®, in order to improve stability.

Because of their aqueous cores, liposomes can be used as carriers for water-soluble substances. A solute which is present in the aqueous core is entrapped in the liposome for a certain time. The release from the vesicle can be passive by diffusion or leakage, or can be activated by trigger mechanisms. A possible trigger mechanism is for instance an increase in temperature resulting in a phase transition of the lipophilic chains of the surfactant molecules in the bilayers.

The retention of the solute in liposomes can, for example, advantageously be used in order to reduce the "first pass effect" of drugs in the liver, to reduce toxicity of substances, to enhance penetration of a substance into the skin, to achieve a sustained release of the solute, for drug targeting to a specific site, or to create a local environment in which the solute is shielded from a second substance in the external phase or in which the solute (e.g. an enzyme) can react with another substance (e.g. a substrate).

Several methods can be used to prepare the different types of liposomes. For a detailed review of the methods of preparation see: N. Weiner et al., Drug Dev. Ind. Pharm., 15 (10) 1523-1554 (1989).

- 3 -

One method is the "film-method". With this method the bilayer forming components are dissolved in an organic liquid (e.g. chloroform, diethyl ether, methanol) or a mixture of such liquids. This solution is rotated in a round-bottom flask, placed in a thermostated water bath, at reduced pressure. The organic solvents evaporate and a film of surfactant molecules is formed on the glass wall at the inside of the flask. The dry film is hydrated by adding an excess of water while shaking. In this way liposomes are formed. The aqueous dispersion of liposomes may be sonicated to achieve a smaller size and smaller size distribution.

Another method is the "reversed phase evaporation method". With this method the bilayer forming components are dissolved in an apolar organic liquid (e.g. chloroform, diethyl ether, isopropyl ether) or a mixture of such liquids. This apolar organic solution is mixed with water by e.g. sonication, forming an emulsion of the water-in-oil type. In this emulsion the surfactant is located at the oil-water interface. Subsequently the excess of organic solvent is removed at reduced pressure and the ratio organic solvent/ water (which is typically 3 or even more at the start) decreases. At this stage the bilayers are formed resulting in gelling of the mixture. Further removal of the organic solvent results in a collapse of the gel and the formation of vesicles (typically LUV's). The obtained product is an aqueous dispersion of vesicles with aqueous cores. After the method of preparation, these vesicles are named REV's (Reversed phase Evaporation Vesicles).

Several other methods can be used to prepare small batches of lipid vesicles. However, all known methods of preparation are related to one or more problems when it comes to upscaling of the process. These are problems of different kind, e.g. the removal of large quantities of explosive and toxic organic solvents, or the impossibility to sonicate large batches.

Irrespective of the method used, all stable lipid vesicles known to date are formed upon hydration of the surfactant, by adding an excess of water or an aqueous solution to a lipid phase containing the surfactant and optionally other lipid

- 4 -

soluble substances (e.g. cholesterol). The resulting vesicles, whether it are liposomes, NIOSOMES®, SUV's, LUV's, REV's, MLV's or "paucilamellar lipid vesicles", all are dispersed in an aqueous, polar phase during the manufacturing process.

5       On preparing the liposomes only a part of the aqueous solution, which may contain for example a water soluble drug, is encapsulated. Therefore, the water-soluble substances are distributed over the aqueous internal and external phases.

10       Often cholesterol is incorporated into the bilayers to modify the properties thereof. In some compositions cholesterol is even an essential component for the formation of the liposomes.

15       Theoretically, also other lipophilic compounds, for instance drugs, can be incorporated into the lipophilic domains of the bilayers. Of course, more lipophilic substance can be incorporated into MLV's than into SUV's or LUV's. However, the bilayers have a highly ordered structure. Very few substances show a good structural fit with these bilayers (cholesterol does). Therefore, in practice very few substances can be incorporated to significant amounts into the lipophilic domains of the bilayers.

20       Moreover, the total volume of the lipophilic domains of the bilayers is small, because of the limited amount of surfactant (typically 30  $\mu$ mol per gram of dispersion) that can be used at the preparation of the vesicles. An unusual high quantity of surfactant, viz. 200  $\mu$ mol per gram, was used by H. Talsma et al. [Drug Dev. Ind. Pharm., 15 (2) 197-207 (1989)].

30       In turn, the limitation of the amount of surfactant, strongly limits the amount of substance that can be incorporated into the lipophilic domains of the bilayers. Therefore, the vesicles known to date are usually not suitable to encapsulate a lipophilic compound. For more details about the encapsulation of substances see: L.D. Mayer et al., Chem. & Phys. Lipids, 40 (1986) 333-345.

35       Because of their aqueous interiors, liposomes are more suitable to encapsulate water-soluble compounds, especially SUV's and LUV's, the latter showing the best encapsulating

- 5 -

efficiencies. Unfortunately, SUV's and LUV's show a much worse retention of the entrapped solute.

Due to the methods of preparation of the vesicles known to date, a substantial amount of aqueous phase is not encapsulated. As a result, also a substantial amount of water-soluble substance is not encapsulated, reducing the encapsulating efficiency to a large extent.

Several disadvantages are related to this low encapsulating efficiency. In the first place, for most applications, the not encapsulated solute has to be removed from the external phase. This means that at least one additional manipulation has to be carried out. For lab-scale quantities of liposome dispersions, this can be done by dialysis. For quantities on an industrial scale it is a major drawback.

In the second place a substantial amount of the compound is lost for its purpose and cannot function in the proper way, which it should do if it were encapsulated. Especially for expensive substances (e.g. peptides) this spill is an important disadvantage.

Because of the disadvantages related to a low encapsulating efficiency, a lot of research is being focused on this problem. Though improvements have been made, the encapsulating efficiency is still far from ideal. Furthermore, the additional techniques which have to be employed in order to improve the encapsulating efficiency (dehydration and rehydration of the liposomes, freeze-thaw procedures and for ionic solutes active entrapment methods) are not suitable for industrial purposes because of the high costs or upscaling problems.

H. Kunieda et al. [J. Am. Chem. Soc. 113(3) 1051-1052 (1991)] has described the formation of reversed vesicles, consisting essentially of the hydrophilic surfactant tetra-ethyleneglycol dodecylether in dodecane. The addition of about 2.5 water molecules/ ethyleneoxide-unit was found to be essential for the formation of the vesicles, which however were found to coalesce and revert back to a lamellar liquid crystalline phase over a period of hours to days.

- 6 -

## SUMMARY OF THE INVENTION

It has now been found that dispersions of stable vesicles in a non-polar phase can be made. Said vesicles, which encapsulate a non-polar phase, comprise a surfactant or a mixture of surfactants, and, if necessary, dependent on the choice of the surfactant(s) and non-polar phase, also a lipophilic stabilizing factor and occasionally a hydrophilic stabilizing factor too.

The invention provides methods for the preparation of said dispersions of vesicles, the methods comprises preparing a mixture of the surfactant(s), the lipophilic stabilizing factor, the non-polar phase and optionally the hydrophilic stabilizing factor, optionally at an elevated temperature and/or by the use of organic solvents, which are subsequently evaporated. Examples thereof are a mixing method, an evaporation method and a film method.

Said dispersions of vesicles can be advantageously incorporated into pharmaceutical, cosmetical, food and pesticide preparations and into preparations for treating surfaces in general.

## LEGENDS TO THE FIGURES

Figure 1 is a schematic representation of a Multilamellar Lipid Vesicle and of a Large Unilamellar Vesicle.

MLV = Multilamellar Lipid Vesicle  
LUV = Large Unilamellar Vesicle  
AC = Aqueous core of liposome  
BL = Bilayer of surfactant molecules  
SB = Sequential Bilayers separated by an aqueous layer  
LD = Lipophilic domain of bilayer consisting of lipophilic tails of surfactant molecules  
HD = Hydrophilic domain of bilayer consisting of aqueous layer plus hydrophilic heads of surfactant molecules  
SM = Surfactant molecule  
LT = Lipophilic tail of surfactant molecule  
HH = Hydrophilic head of surfactant molecule



- 7 -

Figure 2 is a photograph of the vesicles in liquid paraffin of Example 1.1, obtained by the Freeze Fracture Electron Microscopy (FF-EM) technique.

Figure 3 is a graphical representation of the budesonide release from cream formulations 5.1 and 5.2 through a cellulose membrane as a function of the square root of time.

Figure 4 is a graphical representation of the blanching scores caused by the cream formulations 5.3, 5.4 and 5.5 as a function of time after washing off the preparations from the arms.

#### DETAILED DESCRIPTION OF THE INVENTION

It has now been found that stable vesicles in a non-polar phase can be prepared. These vesicles, which encapsulate a non-polar phase, may comprise one or more surfactants, and if necessary, dependent on the choice of the surfactant(s) and non-polar phase, a lipophilic stabilizing factor and occasionally a hydrophilic stabilizing factor too.

The stability of the vesicles according to the invention may be determined by microscopical comparison of the product, shortly after preparation and at any time thereafter, which is at least one week, but preferably several months or years. Stable means that no changes can be observed in the microscopical image and/or in the structural integrity of the vesicles. Stability in the course of time preferably is followed by comparing photographs of the microscopical image, taken at several points of time. The use of a QUANTIMET®-measuring device seems to be most appropriate in this respect.

Said vesicles, as a rule, have a size of between 20 and 100,000 nm, preferably between 40 and 25,000 nm, more preferably between 100 and 5,000 nm. They consist of a non-polar core encapsulated by 1-10,000, preferably 5-2500, more preferably 10-500 spherically closed lamellar sheets. In its turn, these lamellar sheets consist of bilayers of the surfactant molecule(s), the polar head groups of which forming the inner part

of the bilayer and the non-polar chains of the same molecule(s) protruding in the non-polar phase.

The lipophilic stabilizing factor is a molecule characterized by a relatively massive elongated non-polar part and a small polar part. After incorporation of said molecule into the vesicles it will become located in the lipophilic domain of the bilayers, i.e. between the non-polar chains of the surfactant molecules, thereby modifying the hydrocarbon packing stress. It will be appreciated by a person skilled in the art that if the hydrocarbon packing stress is at an appropriate level, the incorporation of the lipophilic stabilizing factor is not required. It has been demonstrated that no such factor is needed e.g. for the preparation of a dispersion of stable vesicles consisting of sucrose-esters in non-polar vehicles such as liquid paraffin and volatile silicone oil. Nevertheless, if said factor would be present, stable vesicles will also be formed according to the present inventors' experience. Examples of the lipophilic stabilizing factor are:

- sterols, such as (partially) hydrogenated 10,13-dimethyl cyclopentaphenanthrenes, optionally substituted by e.g. hydroxyl and carboxylic acid, and esters thereof;
  - retinoids, such as retinoic acid;
  - branched fatty alcohols, such as 2-hexyl octyl ethanol;
  - straight or branched chain (number of C-atoms: 4 or above) saturated aliphatic alcohol esters of aliphatic or aromatic dicarboxylic acids (number of C-atoms: 4 or above), such as dioctyl phthalate;
  - saturated and unsaturated fatty acids, such as palmitic acid, stearic acid and linoleic acid; and
  - straight and branched fatty acid esters with polyhydroxylic compounds, such as propyleneglycol dipelargonate and diglycerol diisostearo stearate,
- but preferably cholesterol is used.

The lipophilic stabilizing factor can be used in a concentration of up to 200 wt%, preferably up to 100 wt% and most preferably 10-50 wt%, based on the amount of surfactant(s) used.

- 9 -

It will be appreciated by a person skilled in the art that the polar part(s) of the surfactant(s) building the structure of the vesicle may be able to interact in the hydrophilic domains of the bilayers in such a way as to sufficiently stabilize the vesicles. This is the case when using e.g. sucrose-esters. However, dependent on the choice of the surfactant, the presence of a hydrophilic stabilizing factor in the vesicles may be required for obtaining stable vesicles.

The hydrophilic stabilizing factor is a small polar molecule (having a molecular weight of up to 150), which has the ability of forming hydrogen-bridges. After incorporation into the vesicles such molecules will be located in the hydrophilic domains of the bilayers, as to contribute to the stability of the vesicles. Said molecule may be water or a compound having one or more functional groups able to form hydrogen-bridges such as a hydroxyl, a (mono- or di-substituted) amino and a carboxylic acid group. Examples of the last-mentioned compound are ethanol and ethanolamine.

In case of polyoxyethylene alkyl ethers, it has been demonstrated that further to the incorporation of a lipophilic stabilizing factor the addition of an amount of water sufficient for the formation of water mediated hydrogen-bridges between the polyoxyethylene chains of the the surfactant used improves the stability of the vesicles of the present invention. The amount of water, to be added for stabilizing purposes, is preferably between  $\frac{1}{2}$  and 2 molecules per oxyethylene-unit. By increasing the amount of water the stability of the vesicles is decreasing. If too much water is added the vesicles of the invention will not be formed anymore or will disintegrate shortly after the formation.

In case of non-POE surfactants the hydrophilic stabilizing factor can be used in a concentration of up to 50 wt%, preferably up to 35 wt% and most preferably 25 wt%, based on the amount of surfactant(s) used.

The vesicles according to the present invention as compared with vesicles in an aqueous phase have a very high encapsulating capacity (which is the amount of encapsulated active ingredient

---

- 10 -

per gram of dispersion) for hydrophilic as well as for lipophilic compounds. The manufacturing process allows a very high encapsulating efficiency (which is the amount of encapsulated active ingredient relative to the total amount of active ingredient in the dispersion) in the vesicles according to the present invention for hydrophilic substances, as compared to the encapsulating efficiency in vesicles in an aqueous phase.

The advantages of the entrapment of hydrophilic as well as lipophilic substances into the vesicles according to the present invention, are broadly speaking the same as those observed after the entrapment of solutes into e.g. liposomes:

- reduction of the first pass effect of drugs in the liver;
- reduction of the toxicity of substances;
- enhancement of the penetration of a substance into the skin;
- achievement of a sustained release of the solute;
- enhancement of the amount of drug released at a specific site;
- creation of a barrier to physically separate 2 incompatible substances, that have to be incorporated into one dosage-form.

Due to the manufacturing method and the choice of the components the vesicles of the present invention also offer some additional advantages in product development, over those already offered by the different types of liposomes, as outlined above:

- the concentration of surfactant, that can be used, is much higher (e.g. up to 1400  $\mu$ mol per gram of dispersion) than that which can be used during the preparation of the several types of liposomes;
- accordingly, the amount of encapsulated substance (hydrophilic and lipophilic) can be much higher;
- the vesicles are very suitable for the incorporation of substances which are not stable in the presence of water or oxygen, under the influence of light or under certain pH-conditions of the polar phase, because the vesicles of the invention can be made without using any water; and

- 11 -

- when no water is used, the vesicles can also be prepared with easily hydrolysible ester surfactants, which cannot be used for the preparation of stable liposomes. After administration of these ester surfactants they will hydrolyse upon contact with water. Another advantage of said biodegradable esters is that they are less toxic.

The surfactants, which are useful in building up the structure of the vesicles according to the invention, may belong to different groups such as for example the non-ionic, anionic, cationic or amphoteric surfactants, and may have an HLB-value of 1-80. Also mixtures of said surfactants, either from the same group or from different groups, can be advantageously used.

Suitable surfactants are for example:

- non-ionic surfactants, such as:
  - sucrose fatty acid esters and mixtures thereof (e.g. WASAG ESTER 7® and WASAG ESTER 15®); polyoxyethylene alkyl ethers (e.g. tri-oxyethyleneglycol monododecyl ether, tri-oxyethyleneglycol monotetradecyl ether, tri-oxyethyleneglycol monohexadecyl ether and tri-oxyethyleneglycol monooctadecyl ether, BRIJ 97® and CETOMACROGOL 1000®); polyoxyethylene sorbitan fatty acid esters (e.g. TWEEN 20®); polyoxyethylene fatty acid esters (e.g. MYRJ 52®); sorbitan esters (e.g. SPAN 80®); glycerol mono- and di-esters of fatty acids; and block copolymers (e.g. polyoxyethylene polyoxypropylene alkyl ethers);
- anionic surfactants, such as:
  - sodium lauryl sulphate, sodium dioctyl sulphosuccinate and alkali metal salts of oleates;
- cationic surfactants, such as:
  - cetyltriethylammonium bromide;
- amphoteric surfactants, such as:
  - betains, such as cocamidopropyl betaine;
- further suitable surfactants, such as lecithines; silicone surfactants; sphingolipids; and some polymerizable surfactants.

- 12 -

The concentration of surfactant(s) will vary according to the surfactant(s) and non-polar excipient(s) used and the application aimed at.

The concentration of total surfactant by weight, based on  
5 the weight of the vesicles-containing dispersion, is, as a rule, between 0.5 and 70%, preferably between 5 and 40%, more preferably between 10 and 30%.

By preference non-ionic surfactants are used. The more preferential surfactants are chosen from the group of the  
10 glycerol mono-esters of fatty acids, the sorbitan esters and the polyoxyethylene alkyl ethers. Most preferably sucrose fatty acid esters are used.

The non-polar phase can be formed from non-polar excipients, which are either solid or liquid at room temperature. Also, mixtures of such non-polar excipients can be advantageously used.  
15

A non-polar excipient according to the present invention is not miscible with water in all proportions at a temperature between 0°C and 100°C, at atmospheric or reduced pressure, or  
20 having a value for the dielectric constant ( $\epsilon$ ) less than 20.0, at 25°C and atmospheric pressure.

In case the non-polar phase has been formed from a mixture of non-polar excipients, said mixture should not be miscible with water in all proportions at a temperature between 0°C and  
25 100°C, at atmospheric or reduced pressure, or at least one of the components of the mixture has a value for the dielectric constant ( $\epsilon$ ) less than 20.0, at 25°C and atmospheric pressure.

Suitable non-polar excipients are for example:

- straight chain aliphatic alcohols, the number of carbon atoms  
30 being 3 or above;
- waxes, such as jojoba-oil and carnauba wax;
- hydrocarbons, such as liquid paraffin, white soft paraffin, hard paraffins, squalene and isoparaffins;
- ketones, such as 5-methylhexaan-2-on;
- 35 - synthetic esters, such as cetylpalmitate;

- 13 -

- glycerol tri-esters of higher saturated and unsaturated fatty acids having 10-30 carbon atoms, such as glyceryltrilaurate and hydrogenated castor oil;
- vegetable oils such as coconut-oil and peanut-oil;
- 5 - silicone oils, such as the volatile silicone oils (e.g. octamethyl cyclotetrasiloxane (ABIL K 4®), decamethyl cyclopentasiloxane, dodecamethyl cyclohexasiloxane).

Preferably, non-polar excipients from the group of the hydrocarbons and from the group of the volatile silicone oils  
10 are used. More preferably mineral oil (=liquid paraffin) and octamethyl cyclotetrasiloxane are used.

The choice of the surfactant(s) as well as of the non-polar excipient(s) depends not only on the substances per se, but also is dependent on the intended application, and of the  
15 preferred manufacturing process.

The vesicles according to the invention can be characterized by methods commonly known in the art. Examples of these methods are: Freeze Fracture Electron Microscopy (FF-EM), Light Scattering techniques, such as Dynamic Light Scattering (DLS)  
20 especially for small vesicles, and X-ray diffraction and neutron diffraction techniques. The vesicles, described in the examples hereafter, were characterized by FF-EM and by means of polarized light microscopy. This last-mentioned technique has been very useful in detecting crystals of the active substances, used in  
25 the examples. An example of a photograph, obtained by the FF-EM technique, is shown in Figure 2.

The dispersion of vesicles according to the present invention can be prepared by methods, which comprise preparing an homogeneous mixture of the surfactant(s), the lipophilic stabilizing factor, the non-polar phase and optionally the hydrophilic  
30 stabilizing factor, optionally at an elevated temperature and/or by the use of organic solvents, which are subsequently evaporated. Examples thereof are a mixing method, an evaporation method and a film method, which are discussed hereafter. The two  
35 last-mentioned methods are allied to methods for the preparation of different types of vesicles in aqueous vehicles as known in

- 14 -

the art: the reversed phase evaporation method and the film method respectively.

The mixing method comprises the steps of:

- mixing, without high sheer being required, all components (which are the surfactant(s) and non-polar excipient(s) and may also be the lipophilic stabilizing factor and the hydrophilic stabilizing factor) at a temperature at or above that at which all ingredients are molten or dissolved; and
- if necessary cooling to room temperature, while stirring.

Cooling can be carried out actively with methods known in the art. Active substances, such as drugs and colouring agents, can be incorporated into the vesicles, by adding them to the non-polar phase before mixing and heating, if necessary.

The evaporation method comprises the steps of:

- dissolving the surfactant(s), the lipophilic stabilizing factor and, if present, the hydrophilic stabilizing factor in a (mixture of) polar organic solvent(s), if necessary at an elevated temperature;
- adding the clear solution of surfactant(s) to the non-polar phase at a temperature at or above the temperature of the surfactant solution;
- preferably agitating the resulting mass and allowing the polar organic solvent(s) to evaporate, if necessary under reduced pressure; and
- if necessary cooling to room temperature, preferably whilst stirring.

When using the evaporation method, the choice of a (mixture of) polar solvent(s) is essential. It is important to choose such a (mixture of) solvent(s) as to enable the dissolution of the surfactant(s) and the stabilizing factor(s) at a suitable temperature. A further requirement which has to be met is the non-mixability of said (mixture of) solvent(s) with the non-polar phase. Preferred polar solvents are ethanol and acetone.

Having obtained a clear solution of the surfactant(s) and the stabilizing factor(s), this is added to the non-polar phase. To prevent a delay in the manufacturing process the temperature of the non-polar phase preferably is the same as that of the



- 15 -

solution. During the subsequent mixing of the two phases the polar phase is allowed to evaporate. This process can be accelerated by reducing the pressure.

When the polar phase is completely evaporated the non-polar phase is cooled to ambient temperature, if necessary. This cooling can be carried out actively with methods known in the art.

Preferably active substances, such as drugs, which are to be incorporated into the vesicles, will be dissolved in the polar phase, unless the solubility in the non-polar phase would be much better. The same holds for the lipophilic stabilizing factor and the hydrophilic stabilizing factor.

The film method comprises the steps of:

- dissolving the surfactant(s), the lipophilic stabilizing factor and, if present, the hydrophilic stabilizing factor in a (mixture of) organic solvent(s);
- removing the organic solvent, using the rotational evaporation technique;
- solvatating the residue in the non-polar phase, if necessary at a temperature above the melting point of the surfactant(s);
- and
- if necessary cooling to room temperature.

When the film method is used the (mixture of) surfactant(s) and the stabilizing factor(s) are dissolved in a suitable (mixture of) organic solvent(s), easy to remove by evaporation. Preferred organic solvents are dichloromethane, chloroform and methanol. The solution, comprising the surfactant(s) and the stabilizing factor(s), is transferred to a roundbottom flask. After the complete evaporation of the solvent(s) by a rotational evaporation technique, the film which has been formed at the inside of the flask, is solvatated with a non-polar phase at a temperature above the melting point of the surfactant(s). After finishing the solvatating process, the dispersion of vesicles in the non-polar medium is cooled to ambient temperature, if necessary. This cooling can be carried out actively with methods as known in the art.

- 16 -

Preferably the active substances, such as drugs and colouring agents, which are to be incorporated into the vesicles, are added to the solution, comprising the surfactant(s), unless the solubility of those substances in the non-polar phase would be much better than in the solution of surfactant(s). The same holds for the lipophilic stabilizing factor and the hydrophilic stabilizing factor.

It will be appreciated that the choice of the method is determined by the components of the vesicles, the batch size to be achieved and the physico-chemical properties of the surfactant(s), the (biologically) active compound(s), the additives and the non-polar excipient(s) such as melting point, solubility in different media, volatility, behaviour at elevated temperatures and so on.

After having obtained a dispersion of vesicles according to one of the above-mentioned method, additional production steps comprise:

- reducing the size of the vesicles by methods known in the art (sonication, extrusion, microfluidization);
- polymerizing the vesicles in case a polymerizable surfactant is used by methods known in the art;
- removing the non-polar excipient(s) to obtain an instant preparation
- adding to the vesicles in non-polar media an appropriate aqueous or non-aqueous polar liquid, a gel based on such liquids, a liquid or semisolid lipid, or a mixture of any of the above, to make a solution, a gel, a water-in-oil emulsion, an oil-in-water emulsion, or an ointment;
- incorporating hydrophilic or lipophilic substances, such as drugs and colouring agents, into the vehicles, which comprise a dispersion of vesicles according to the invention.

Aqueous or non-aqueous polar liquids can be added to the dispersions of vesicles according to the invention, without disturbing the structure of the vesicles. However, due to the polar character of the vehicle to be added, the outer layer of the vesicles could get lost. Accordingly, for this kind of

- 17 -

preparations it is a prerequisite to use dispersions containing multilamellar vesicles.

Liquid or semi-solid lipids may be mixed, as such or in a w/o or o/w emulsion, with the vesicles according to the invention. When a w/o or an o/w emulsion is used, to be mixed with the vesicles according to the invention, it will also contain an appropriate w/o or o/w emulsifier, as known in the art of making such w/o or o/w emulsions. Said emulsifiers have to be chosen carefully as to avoid the destruction of the vesicles.

The dispersions of vesicles of the present invention and/or the vehicles comprising said dispersions may also contain buffers, preservatives, anti-oxidants, moisturizers, penetration enhancers, UV absorbers, dyes, fragrances, flavours, sweeteners, pesticides, insect repellants etc..

As already mentioned, drugs may be advantageously incorporated into the vesicles and/or into the vehicles comprising the dispersion of vesicles according to the invention. As there seems to be no limitation with respect to the route of administration for the preparations mentioned, a variety of drugs can be incorporated therein, such as e.g. steroidal compounds, dithranol, nicotinic acid and derivatives thereof, retinoids, peptides, anti-inflammatory agents, anti-proliferative agents, antimicrobials and vitamins. This list of drugs should not be considered as a limitative enumeration. For practical reasons there is a preference for low-dose active ingredients to be incorporated into the vesicles. The vesicles in non-polar phase according to the present invention seem especially suited for the incorporation of drugs, which structurally resemble one of the components of the vesicles such as the steroidal compounds and vitamin A acid or derivatives.

The preference for the organic solvents to be used is determined for a great deal by the application aimed at: in certain categories of products, especially in the pharmaceutical, cosmetical, food and pesticide processing field, no sig-

- 18 -

nificant amounts of certain organic solvents in the final products are allowed.

Especially if the dispersions of vesicles according to the present invention are used for the preparation of pharmaceutical dosage-forms, the components thereof should meet high standards regarding purity. The choice of these surfactant(s) and non-polar excipient(s) further depends on whether the pharmaceutical preparation, comprising the dispersion of vesicles according to the invention, is meant to be applied via the oral, the topical, the nasal, the rectal, the pulmonal or the parenteral (i.e. intravenous, intramuscular or subcutaneous) route.

However, the application of the dispersions of vesicles according to the present invention is not considered to be limited to pharmaceutical purposes. The incorporation of said dispersion of vesicles into for example cosmetic, food and coating preparations for the treatment of surfaces in general is thought to be of great value.

The applications of the vesicles according to the invention may be based on the following concepts:

- empty vesicles in a vehicle without any additional active ingredient;
- empty vesicles in a vehicle to which an active ingredient has been added;
- loaded vesicles in a vehicle without any additional active ingredient;
- and loaded vesicles in a vehicle to which an active ingredient has been added.

Examples for products, based on the vesicles according to the invention are:

- a cleansing product for the removal of grease and dirt;
- a detoxifying product for the removal of undesired toxic substances from the body;
- a product in which two incompatible compounds have been incorporated e.g. a cream, containing salicylic acid and vesicles, loaded with a corticosteroid;

- 19 -

- a product in which a fast and a sustained release of the active ingredient are combined;
- encapsulation of water-soluble moisturizers in cosmetic preparations;
- 5 - encapsulation of vitamin C in fruit juices;
- encapsulation of nicotine in chewing gum; and
- a product, comprising empty vesicles, built up from essential fatty acids, and a corticosteroid.

10 All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

15 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit and scope of the appended claims.

20 The following examples further illustrate the invention.

- 20 -

## EXAMPLES

## Example 1

## Production of dispersions of vesicles in a non-polar medium

5

1.1. Vesicles in liquid paraffin were made as follows:

6 g of WASAG ESTER 15® and 600 mg of cholesterol were dissolved in 200 ml of acetone. To the resulting solution 300 g of liquid paraffin were added and this mixture was vigorously stirred at 70°C, using a TURRAX® homogenizer, in order to remove the solvent acetone by evaporation. The resulting dispersion was cooled to roomtemperature whilst stirring. The polarized light-microscope image of the resulting dispersion revealed the presence of a multiplicity of Maltese crosses, which may be considered as a measure for the amount of vesicles. The resulting (multilamellar) vesicles consisted of more than 20 bilayers (concluded from FF-EM photographs, see Figure 2) and had a mean diameter of 800 nm (calculated from these FF-EM photographs).

20 1.2. Another batch of vesicles in liquid paraffin was produced as follows:

70 g of liquid paraffin was heated and degassed at 80°C. 30 g of WASAG ESTER 15® en 3 g of cholesterol were dissolved in 80 g of ethanol at 70°C. The clear ethanolic solution was mixed with the liquid paraffin using a stirrer at 150 rpm. The ethanol was removed under reduced pressure at 80°C. It was assumed that all ethanol was removed when the foaming of the dispersion disappeared. The resulting dispersion of vesicles was cooled under reduced pressure to 22°C. The resulting (multilamellar) vesicles consisted of more than 20 bilayers (concluded from FF-EM photographs) and had a mean diameter of 800 nm (calculated from these FF-EM photographs). The vesicles were stable for at least 1 year.

35 1.3. Another batch of vesicles was produced in the same way -and using the same ingredients- as 1.2., with the following amounts:

- 21 -

50 g of WASAG ESTER 15<sup>®</sup> and 5 g of cholesterol dissolved in ethanol at 70°C and 250 g of liquid paraffin.

1.4. Another batch of vesicles was made in a volatile silicon oil as follows:

70 g of ABIL K4<sup>®</sup> silicon oil, 30 g of WASAG ESTER 15<sup>®</sup> and 3 g of cholesterol were mixed at 80°C using a stirrer at 150 rpm. After 45 minutes the mixture was cooled to 22°C. The resulting vesicles had a mean diameter of 1  $\mu$ m.

10

1.5. Yet another batch of vesicles was made in liquid paraffin as follows:

97.5 g of liquid paraffin, 2 g of tri-oxyethyleneglycol monooctadecyl ether and 0.5 g of cholesterol were mixed at 70°C using a stirrer at 150 rpm. After 45 minutes the mixture was cooled to 22°C. The resulting vesicles had a mean diameter of 1  $\mu$ m.

1.6. Another batch of vesicles was made in dodecane as follows:

96.5 g of dodecane, 2.5 g of Brij-30<sup>®</sup> (tetra-ethylene-glycol monolaurylether), 2.5 g of cholesterol and 1 g of water were mixed at 80°C using a stirrer at 300 rpm. After 15 minutes the container with the mixture was placed in an ultra-sonic device and cooled to 25°C, whilst sonicating for 10 minutes. The resulting multi-lamellar vesicles had a diameter up to 10  $\mu$ m. After 3 weeks the mixture contained besides vesicles, also crystals of cholesterol.

In case the addition of cholesterol was omitted, in order to prepare the vesicles as described by H. Kunieda et al. [J. Am. Chem. Soc. 113(3) 1051-1052 (1991)], vesicles could not be obtained, neither by sonicating the mixture nor by handshaking.

In case the concentrations of water and Brij-30<sup>®</sup> were increased tenfold, vesicles were obtained in the absence of cholesterol. These vesicles disintegrated within about 5 weeks.

- 22 -

1.7. Another batch of vesicles was made in a volatile silicon oil as follows:

20 g of ABIL-K4® silicon oil, 1 g of Arlacel-40® (sorbitan monopalmitate), 0.4 g of cholesterol and 0.2 g of water were  
5 mixed at 85°C using a stirrer at 300 rpm. After 30 minutes the container with the mixture was placed in an ultra-sonic device and cooled to 28°C, whilst sonicating for 10 minutes. The resulting multi-lamellar vesicles were stable for at least 3 weeks and had a diameter up to 5 µm.

10 In case the addition of cholesterol was omitted, vesicles could not be obtained.

Leaving out the addition of water resulted in the formation of vesicles, but the resulting vesicles were less stable and disintegrated within a few days.

15 Replacing the water by 0.15 g of ethanolamine also yielded stable vesicles with a diameter up to 5 µm.

1.8. Another batch of vesicles was made in a volatile silicon oil as follows:

20 20 g of ABIL-K4® silicon oil, 1 g of glycerylmono-laurate, 0.4 g of cholesterol and 0.2 g of water were mixed at 85°C using a stirrer at 300 rpm. After 30 minutes the container with the mixture was placed in an ultra-sonic device and cooled to 28°C, whilst sonicating for 10 minutes. The resulting multi-lamellar  
25 vesicles were stable for at least 3 weeks and had a diameter up to 15 µm.

In case the addition of cholesterol was omitted, vesicles could not be obtained.

30 Leaving out the the addition of water resulted in the formation of vesicles, but the resulting vesicles were less stable and disintegrated within a few days.

Replacing the water by 0.2 g of ethanolamine also yielded stable vesicles with a diameter up to 15 µm.

35 1.9. Other lipid vesicles were made in a volatile silicon oil as follows:



- 23 -

30 g of ABIL K4<sup>®</sup> silicon oil, 3 g of WASAG ESTER 15<sup>®</sup> and 0.3 g of palmitic acid were mixed at 85°C using a stirrer at 300 rpm. After 10 minutes the mixture was cooled to ambient temperature. The resulting lipid vesicles had a mean diameter of 1 µm. If palmitic acid was not added, the sample showed a large amount of aggregated lipid vesicles and non-vesicular material.

1.10. Other lipid vesicles were made in a volatile silicon oil as follows:

20 g of ABIL K4<sup>®</sup> silicon oil, 1 g of WASAG ESTER 15<sup>®</sup> and 0.1 g of retinoic acid were mixed at 85°C using a stirrer at 300 rpm. After 10 minutes the mixture was cooled to ambient temperature. The resulting lipid vesicles had a mean diameter of 1 µm. If retinoic acid was not added, the sample showed a large amount of aggregated lipid vesicles and non-vesicular material.

1.11. Other lipid vesicles were made in a volatile silicon oil as follows:

20 g of ABIL K4<sup>®</sup> silicon oil, 1 g of WASAG ESTER 15<sup>®</sup> and 0.1 g of propyleneglycol-dipelargonate were mixed at 85°C using a stirrer at 300 rpm. After 10 minutes the mixture was cooled to ambient temperature during sonification. The resulting lipid vesicles had a mean diameter of 1 µm. If instead of propyleneglycol-dipelargonate 0.1 g of diglyceryl-di-isostearo-stearate was used, the same amount of vesicles was obtained. If WASAG ESTER 15<sup>®</sup> alone was used, the sample showed a large amount of aggregated lipid vesicles and non-vesicular material.

1.12. Other lipid vesicles were made in a volatile silicon oil as follows:

10 g of ABIL K4<sup>®</sup> silicon oil, 1 g of WASAG ESTER 15<sup>®</sup> and 0.33 g of 2-hexyl-octyl-ethanol were mixed at 90°C using a stirrer at 300 rpm. After 10 minutes the mixture was cooled to ambient temperature during sonification. The resulting lipid

- 24 -

vesicles had a mean diameter of 1  $\mu\text{m}$ . If instead of 2-hexyl-octyl-ethanol 0.33 g of dioctylphthalate was used, the same amount of vesicles was obtained. If WASAG ESTER 15® alone was used, the sample showed a large amount of aggregated lipid vesicles and non-vesicular material.

1.13. Other lipid vesicles were made in a volatile silicon oil as follows:

36 g of ABIL K4® silicon oil, 2.7 g of freeze dried Cocamidopropyl betaine (TEGO-BETAIN HS®) and 0.34 g of cholesterol were mixed at 85°C using a stirrer at 300 rpm. After 10 minutes the mixture was cooled to ambient temperature during sonification. The resulting lipid vesicles had a mean diameter of 1  $\mu\text{m}$ . If cholesterol was not added, the sample showed very few vesicles and most of the Cocamidopropyl betaine was in a crystalline form.

1.14. Other lipid vesicles were made in a volatile silicon oil as follows:

25 g of ABIL K4® silicon oil, 3 g of freeze dried potassium oleate, 1 g of cholesterol and 1 g of water were mixed at 85°C using a stirrer at 300 rpm. After 10 minutes the mixture was cooled to ambient temperature during sonification. The resulting lipid vesicles had a mean diameter of 1  $\mu\text{m}$ .

If cholesterol was not added, the sample showed very few vesicles and most of the potassiumoleate was in a crystalline form.

If water was not added, the sample showed very few vesicles and most of the potassiumoleate was in a crystalline form.

If only potassiumoleate was used, the sample showed very few vesicles and most of the potassiumoleate was in a crystalline form.

- 25 -

**Example 2****Production of dispersions of  
loaded vesicles in a non-polar medium**

5        2.1. Vesicles loaded with disodium-fluorescein were made  
in the same way as 1.1, using the following ingredients:

65 mg of disodium-fluorescein, 20 g of WASAG ESTER 15®  
and 2 g of cholesterol dissolved in 80 g of ethanol at 70°C  
and 100 g of liquid paraffin.

10      The resulting vesicles had a diameter of 1  $\mu$ m and showed a  
bright fluorescence typical for disodium-fluorescein. No crys-  
tals of disodium-fluorescein have been seen in this dispersion  
(examined by a polarized light microscope). Because of the  
extremely low solubility of disodium-fluorescein in liquid  
15      paraffin it was concluded that all disodium-fluorescein was  
encapsulated within the vesicles.

2.2. Another batch of vesicles loaded with the cortico-  
steroid budesonide was made in the same way as 1.1, using the  
20      following ingredients:

381 mg of budesonide, 50 g of WASAG ESTER 15® and 5 g of choles-  
terol dissolved in 100 ml of ethanol at 70°C and 250 g of liquid  
paraffin at 80°C.

The resulting vesicles had a diameter of 1  $\mu$ m. No crystals of  
25      budesonide have been seen in the sample. Because of the extreme-  
ly low solubility of budesonide in liquid paraffin it was con-  
cluded that all budesonide was encapsulated within the vesicles.

2.3. Yet another batch of vesicles loaded with gramicidine  
30      D was made in the same way as 1.1, using the following ingredi-  
ents:

100.6 mg of gramicidine D, 20 g of WASAG ESTER 15® and  
2 g of cholesterol dissolved in 100 ml of ethanol at 70°C and  
100 g of liquid paraffin at 80°C.

35      The resulting vesicles had a diameter of 1  $\mu$ m. No crystals of  
gramicidine D have been seen in the sample. Because of the  
extremely low solubility of gramicidine in liquid paraffin it

- 26 -

was concluded that all gramicidine D was encapsulated within the vesicles.

2.4. Yet another batch of vesicles loaded with the corticosteroid hydrocortison-17-butyrate was made in the same way as 1.1, using the following ingredients:

250 mg of hydrocortisone-17-butyrate, 30.1 g of WASAG ESTER 15<sup>®</sup> and 3 g of cholesterol dissolved in 50 ml ethanol at 70°C and 70 g of liquid paraffin at 80°C.

10 The resulting vesicles had a diameter of 1  $\mu$ m. No crystals of hydrocortisone-17-butyrate have been seen in the sample. Because of the extremely low solubility of hydrocortison-17-butyrate in liquid paraffin it was concluded that all hydrocortisone-17-butyrate was encapsulated within the vesicles.

15

2.5. Yet another batch of vesicles loaded with hydrocortisone-17-butyrate was made in the same way as 1.3 using the following ingredients:

70 g of ABIL K4<sup>®</sup>, 30 g of WASAG ESTER 15<sup>®</sup>, 3 g of cholesterol and 0.25 g of hydrocortison-17-butyrate.

20 The resulting vesicles had a mean diameter of 1  $\mu$ m. No crystals of hydrocortisone-17-butyrate have been seen in the sample. Because of the extremely low solubility of hydrocortisone-17-butyrate in ABIL K4<sup>®</sup> it was concluded that all hydrocortisone-25 17-butyrate was encapsulated within the vesicles.

2.6. Vesicles loaded with methyl-p-hydroxybenzoate (NIPAGIN M<sup>®</sup>) were made in the same way as 1.1., using the following ingredients:

30 400 mg of NIPA M<sup>®</sup>, 20 g of WASAG ESTER 15<sup>®</sup> and 2 g of cholesterol dissolved in 80 g of ethanol at 70°C and 177.6 g of liquid paraffin.

The resulting vesicles had a mean diameter of 1  $\mu$ m. There were no crystals of NIPA M<sup>®</sup> present in this sample (examined by a 35 polarized light microscope).

- 27 -

1 g of the sample was centrifuged at 3000 RPM for 10 minutes using a HERAEUS CHRIST MINIFUGE 2 centrifuge to separate the vesicles from the external paraffin phase.

50  $\mu$ l of the clear external phase was extracted with 2 ml of a 75% propyleneglycol/water mixture. The UV absorption of the extract at 274.8 nm was measured using a SHIMADZU UV-160 spectrophotometer. The amount of NIPA M was calculated using a calibration curve of 6 calibration solutions. The concentration of NIPA M found in the external phase was 46.8  $\mu$ g/ml (N=2), the measured saturation concentration of NIPA M in liquid paraffin is 55  $\mu$ g/ml.

It was calculated that 97.3% (N=2) of the total amount of NIPA M in the sample was encapsulated within the vesicles.

15

### Example 3

#### Production of a conventional cream, and of a cream containing a dispersion of empty vesicles

3.1. A conventional cream was produced as follows:

3000 g of white soft paraffin, 1200 g of liquid paraffin, 1440 g of cetylstearyl alcohol and 40 g of methyl-p-hydroxybenzoate (NIPAGIN M®) were heated together at 70°C. 360 g of CETOMACROGOL 1000®, 84 g of anhydrous citric acid and 56 g of anhydrous tri-sodium-citrate were dissolved in 13820 g of water at 70°C. Both phases were mixed together, concurrently using a stirrer at 200 rpm and a TURRAX® homogenizer at 2000 rpm. The dispersion was cooled under reduced pressure to 22°C.

3.2. A cream containing vesicles was produced as follows:

50 g of the dispersion according to 1.2 was mixed with 200 g of the cream according to 3.1 for 30 minutes at 20°C with a stirrer at 50 rpm. After 3 months the vesicles were still homogeneously distributed over the cream (observed by a polarized light microscope).

35

- 28 -

**Example 4****Production of a conventional gel, and a gel  
containing a dispersion of empty vesicles**

5        4.1. A conventional gel was produced by dispersing 10 g  
of CARBOPOL 934® in 990 g of water. The pH of the resulting  
suspension was adjusted to pH = 4.0 with triethanolamine.

10       4.2. A gel containing vesicles was produced by handmixing  
0.8 g of the dispersion according to 1.2 with 3.2 g of the gel  
according to 4.1 in a mortar.  
The resulting gel had a creamy appearance. The vesicles were  
homogeneously distributed over the gel (observed by a polarized  
light microscope). The vesicles were stable for at least 1 year.

15

**Example 5****Production of creams, containing a dispersion of vesicles  
and a medicament (free or encapsulated in the vesicles)  
or a medicament alone**

20

5.1. A cream containing budesonide encapsulated in vesicles  
was produced by mixing (with a stirrer at 50 rpm) during half  
an hour 50 g of the dispersion according to 2.2 with 200 g of  
the cream according to 3.1.

25

5.2. A cream containing free budesonide and vesicles was  
produced by mixing (with a stirrer at 50 rpm) during 30 minutes  
50 g of the cream according to 3.2 with 12.5 mg of budesonide.

30

5.3. A cream containing hydrocortison-17-butyrate encapsu-  
lated in vesicles was produced by handmixing in a mortar 4 g of  
the dispersion according to 2.4 with 6 g of the cream according  
to 3.1.

35

5.4. A cream containing hydrocortison-17-butyrate encapsu-  
lated in vesicles was produced by handmixing in a mortar 4 g of

- 29 -

the dispersion according to 2.5 with 6 g of the cream according to 3.1.

5.5. A cream containing hydrocortison-17-butyrate without vesicles was prepared by handmixing in a mortar 10 mg of hydrocortison-17-butyrate with 10 g of the cream according to 3.1.

#### Example 6

Production of gels containing a dispersion of vesicles and disodium-fluorescein (free or encapsulated within the vesicles) or disodium-fluorescein alone

6.1. A gel containing encapsulated disodium-fluorescein in vesicles was produced by handmixing in a mortar 0.8 g of the dispersion according to 2.1 with 3.2 g of the gel according to 4.1. After 6 months the vesicles were still homogeneously distributed over the gel.

6.2. A gel containing free disodium-fluorescein and vesicles was produced by dissolving 1 mg disodium-fluorescein in 10 g of the gel according to 4.2. After 6 months the vesicles were still homogeneously distributed over the gel.

6.3. A gel containing disodium-fluorescein alone was produced by dissolving 1 mg of disodium-fluorescein in 10 g of the gel according to 4.1.

#### Example 7

In vitro budesonide release from creams containing a dispersion of vesicles

The creams according to 5.1 and 5.2 were compared in the following in vitro diffusion test.

The in vitro budesonide release experiments were performed at a temperature of 35°C using a perspex donor compartment in which the cream layer (1.8 mm) was separated from the aqueous acceptor phase (0.5% w/w CETOMACROGOL 1000®) by a cellulose-

- 30 -

triacetate membrane (SM 14539, SARTORIUS®, The Netherlands) with a surface area of 52.8 cm<sup>2</sup>. 100 ml acceptor phase was circulated through the acceptor chamber at a rate of about 1.8 ml/min. Samples of 1 ml were taken with 30 minutes intervals. After  
5 sampling the acceptor phase was filled up to 100 ml with 1 ml fresh acceptor phase. The budesonide concentrations in the samples were determined using HPLC. 50 µl samples were injected to the system with the aid of an automatic injector (GILSON® MODEL 231). The reversed phase HPLC column (CHROMSPHER® C18  
10 100 x 3 mm, CHROMPACK®, The Netherlands) was eluted at 22°C with a mobile phase consisting of acetonitrile/water (35/65 v/v) at a flow rate of 0.8 ml/min. The column effluent was monitored at 242 nm (APPLIED BIOSYSTEMS® 757). The retention time of the budesonide was about 7 minutes.  
15 Both creams were tested in duplicate, the maximal deviation between the results of one preparation being 8%.  
In Figure 3 the amount of budesonide penetrated through the membrane (as described above) is shown as a function of the squareroot of application time.  
20 From these results it appeared that encapsulation of budesonide in vesicles within a cream significantly retarded the release of budesonide from such a cream.

#### Example 8

##### 25      The influence of encapsulation on the fluorescence          behaviour of disodium-fluorescein

The fluorescence behaviour of disodium-fluorescein in the gels according to 6.1, 6.2 and 6.3 were studied with reflected  
30 light fluorescence microscopy (RLFM).

A RLFM microscope (OLYMPUS® BH2, Japan) with blue light excitation was used to study the fluorescence pattern of gels 6.1, 6.2 and 6.3. The images of the microscope were registrated by a video camera (SONY® DXC-3000P) and taped with a video-  
35 recorder (SONY® VO 5800PS).

With the aid of the described apparatus it was possible to measure the time after which fluorescence disappeared within



- 31 -

the gels. For the gels 6.1, 6.2, 6.3 this time was resp.: 469, 53 seconds and less then 1 second.

From these results it was clear that the highly water-soluble disodium-fluorescein was still encapsulated in the vesicles  
5 after dispersing them in a gel.

#### Example 9

##### In vivo corticosteroid release on human skin

10 The in vivo skin blanching effect of the corticosteroid creams according to 5.3, 5.4 and 5.5 were compared in a McKenzie-Stoughton test.

The test was conducted on a panel of non-patient volunteers (1 female and 7 males). Sites were marked on the flexor aspect  
15 of both forearms by light indentation with a circular punch of 15 mm diameter. Sites were at least 4 cm distant from wrist and elbow. The precoded preparations were applied to these sites according to a Latin square experimental design. Preparations were applied in amounts of 10  $\mu$ l per site from a disposable  
20 pipette (Capilettor®). The application sites were then covered, but not occluded with a "guard", which was held in place with a ring of surgical tape (diameter: external 50/60 mm, internal 25 mm).

Dressings were removed and arms were washed with soap and  
25 lukewarm water 9 hours after application of the formulations. Accordingly, blanching at the various sites was visually assessed on an integral scale of 0-4 by two experienced scorers, working independently of each other. This was done at 1, 3, 6, 9, 25, and 32 hours after removal of the preparations. The  
30 experiment was conducted in a double-blind fashion.

The results of this test are shown in Figure 4 where the mean blanching scores are given as a function of time.

From these results it was concluded that the absolute amount of the steroid which reaches the deep skin department (where  
35 blanching is caused) from creams 5.1 and 5.2 were lower than those from the conventional cream 5.3. This was caused by the

- 32 -

slower release and the retention of hydrocortison-17-butyrate due to its encapsulation.

The conventional cream had a peak score after 3 hours (2.64) the score rapidly decreased to 1.87 after 9 hours. Both creams  
5 with hydrocortison-17-butyrate encapsulated in multilamellar vesicles did not show such a fast decrease.

From these results it appeared that vesicles could be used to establish a sustained release of a medicament from a dermatological formulation and a retention in the upper skin regions.

- 33 -

CLAIMS

1. A dispersion of stable vesicles in a non-polar phase, the vesicles, which encapsulate a non-polar phase, comprising  
5 a surfactant or a mixture of surfactants and a lipophilic stabilizing factor.

2. A dispersion of vesicles according to claim 1, wherein the vesicles comprise a hydrophilic stabilizing factor.

10

3. A dispersion of vesicles according to claim 1 or 2, wherein the lipophilic stabilizing factor is a compound selected from the group consisting of:

- sterols, such as (partially) hydrogenated 10,13-dimethyl  
15 cyclopentaphenanthrenes, optionally substituted by e.g. hydroxyl and carboxylic acid, and esters thereof;
- retinoids, such as retinoic acid;
- branched fatty alcohols, such as 2-hexyl octyl ethanol;
- straight or branched chain (number of C-atoms: 4 or above)  
20 saturated aliphatic alcohol esters of aliphatic or aromatic dicarboxylic acids (number of C-atoms: 4 or above), such as dioctyl phthalate;
- saturated and unsaturated fatty acids, such as palmitic acid, stearic acid and linoleic acid; and
- 25 - straight and branched fatty acid esters with polyhydroxylic compounds, such as propyleneglycol dipelargonate and diglycerol diisostearo stearate.

4. A dispersion of vesicles according to any one of claims  
30 1-3, wherein the lipophilic stabilizing factor is cholesterol.

5. A dispersion of vesicles according to any one of claims 2-4, wherein the hydrophilic stabilizing factor is a polar liquid selected from the group consisting of water and a small  
35 compound having a molecular weight of up to 150 and having one or more functional groups able to form hydrogen-bridges such as

a hydroxyl, a (mono- or di-substituted) amino and a carboxylic acid group, such as ethanol and ethanolamine.

6. A dispersion of vesicles according to any one of claims  
5 1-5, the vesicles comprising a non-ionic surfactant.

7. A dispersion of vesicles according to claim 6, wherein the non-ionic surfactant is a sucrose fatty acid ester.

10 8. A dispersion of vesicles according to any one of claims 1-7, wherein the non-polar phase consists of a liquid paraffin or a volatile silicone oil.

9. A dispersion of vesicles according to any one of claims  
15 1-8, wherein one or more hydrophilic (biologically) active agents are present in the non-polar phase and/or entrapped in the vesicles.

10. A dispersion of vesicles according to any one of claims  
20 1-9, wherein one or more lipophilic (biologically) active agents are present in the non-polar phase and/or entrapped in the vesicles.

11. A method for the preparation of a dispersion of stable  
25 vesicles, which encapsulate a non-polar phase, in a non-polar phase, the vesicles comprising a (mixture of) surfactant(s), a lipophilic stabilizing factor and occasionally a hydrophilic stabilizing factor, the method comprises mixing the surfactant(s), the lipophilic stabilizing factor, the non-polar  
30 phase and optionally the hydrophilic stabilizing factor.

12. A method according to claim 11, which comprises mixing the surfactant or the mixture of surfactants, the lipophilic stabilizing factor and optionally the hydrophilic stabilizing  
35 factor with the non-polar phase at or above the temperature at which all components are molten or dissolved.

- 35 -

13. A method according to claim 11, which comprises the steps of:

- dissolving the surfactant or the mixture of surfactants, the lipophilic stabilizing factor and optionally the hydrophilic stabilizing factor in a (mixture of) polar organic solvent(s),  
5 if necessary at an elevated temperature;
- adding the clear solution to the non-polar phase at or above the temperature of the surfactant solution; and
- preferably mixing the solution meanwhile;
- 10 - allowing the polar organic solvent(s) to evaporate; and
- if necessary cooling to room temperature, preferably whilst stirring.

14. A method according to claim 11, which comprises the steps of:

- dissolving the surfactant or the mixture of surfactants, the lipophilic stabilizing factor and optionally the hydrophilic stabilizing factor in a (mixture of) organic solvent(s);
- removing the organic solvent(s) using the rotational evaporation technique; and  
20
- solvatating the residue in the non-polar phase at a temperature above the melting point of the surfactant(s).

15. A method according to any one of claims 11-14, which  
25 further comprises the incorporation of an active substance into the vesicles by adding said substance to the solution, which contains the surfactant(s).

16. Use of the dispersion of vesicles according to any  
30 one of claims 1-11 or prepared according to any one of claims 12-15 in pharmaceutical, cosmetical, food and pesticide preparations and in preparations for treating surfaces in general.

FIG. 1/4




FIG. 2/4



525 nm

FIG. 3/4







FIG. 4/4



## INTERNATIONAL SEARCH REPORT

PCT/NL 92/00112

International Application No.

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61K9/127		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY vol. 113, no. 3, 30 January 1991, WASHINGTON, DC, (US) pages 1051 - 1052 H. KUNIEDA ET AL. 'formation of reversed vesicles' cited in the application see the whole document ---	1,2,5,6, 8,11
X	WO,A,9 006 747 (MICRO VESICULAR SYSTEMS, INC.) 28 June 1990 see page 18 - page 19; example 2 ---	1,3,4, 9-12,16
X	WO,A,8 602 264 (LUISI) 24 April 1986 see page 4, line 33 - page 5, line 23 see page 16; example 4 ---	1,2,5,6, 8-11,16
	---	-/--
<p><sup>9</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claim(s) or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to underpin the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Δ" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
08 OCTOBER 1992	09. 11. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	BENZ K.F. <i>Benz</i>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	US,A,3 384 544 (HARROW ET AL.) 21 May 1968 see the whole document; in particular column 5, lines 37-49; column 7, example 6	1,2,5,6, 8-11,16
A	WO,A,8 702 582 (BIOGRAM AB) 7 May 1987 see page 17; example 10	1
A	PATENT ABSTRACTS OF JAPAN vol. 11, no. 43 (C-402)(2490) 7 February 1987 & JP,A,61 207 324 ( AGENCY OF IND SCIENCE & TECHNOL ) 13 September 1986 see abstract	7

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. NL 9200112  
SA 63173**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 08/10/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9006747	28-06-90	US-A- 5019392	28-05-91
		AU-A- 4944690	10-07-90
		CA-A- 2006251	20-06-90
		EP-A- 0449983	09-10-91
-----			
WO-A-8602264	24-04-86	CH-A- 662944	13-11-87
		AU-A- 4961285	02-05-86
		EP-A, B 0197987	22-10-86
-----			
US-A-3384544		None	
-----			
WO-A-8702582	07-05-87	SE-B- 462894	17-09-90
		AU-B- 586513	13-07-89
		AU-A- 6526586	19-05-87
		EP-A, B 0224457	03-06-87
		JP-T- 63501150	28-04-88
		SE-A- 8505086	29-04-87
		US-A- 4931284	05-06-90
-----			